Research programme: vascular targeting agents - JOMED/OXiGENEAlternative Names: Vascular targeting agents - JOMED/OXiGENE
Latest Information Update: 26 Apr 2007
At a glance
- Originator JOMED; OXiGENE
- Developer JOMED
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Coronary artery restenosis; Vascular restenosis
Most Recent Events
- 26 Apr 2007 Discontinued - Preclinical for Vascular restenosis in Europe (Implant)
- 26 Apr 2007 Discontinued - Preclinical for Coronary artery restenosis in Europe (Implant)
- 05 Aug 2002 Preclinical trials in Vascular restenosis in Europe (Implant)